Europe Sjs Ten Treatment Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 1,686.96 Million |
 Market Size (Forecast Year) |
USD 2,737.34 Million |
 CAGR |
% |
| Major Markets Players |
>欧洲 SJS/TEN 治疗市场，按治疗（药物、支持护理、住院、隔离、药膏和其他）、诊断（体检、皮肤活检、病史、血液检查、培养和其他）、病因（特定治疗、感染和其他）、给药途径（口服、肠胃外、外用和其他）、药物类型（品牌和通用）、治疗领域（联合治疗和单一治疗）、患者类型（老年、成人和儿童）、最终用户（医院、专科诊所、门诊手术中心、家庭护理环境和其他）、分销渠道（零售药店、直接招标和其他）划分 - 行业趋势和预测到 2030 年。
欧洲 SJS/TEN 治疗市场分析与洞察
由于史蒂文斯-约翰逊综合征（SJS）和中毒性表皮坏死松解症（TEN）较为罕见，因此这些疾病的治疗市场相对较小。
欧洲SJS/TEN治疗市场以药物为主，因为药物是治疗这些疾病的主要形式。皮质类固醇、静脉注射免疫球蛋白（IVIG）和抗生素是治疗SJS/TEN最常用的药物。
欧洲 SJS/TEN 治疗市场预计将在 2023 年至 2030 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，该市场以 6.4% 的复合年增长率增长，预计将从 2022 年的 16.8696 亿美元达到 2030 年的 27.3734 亿美元。
欧洲 SJS/TEN 治疗市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入来源、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情景，请联系我们获取分析师简报。我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。各地区发展中国家零售单位的可扩展性和业务扩展以及与供应商合作安全分销机器和药品是推动预测期内市场需求的主要驱动力。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
治疗（药物、支持治疗、住院、隔离、药膏等）、诊断（体检、皮肤活检、病史、血液检查、培养等）、病因（具体治疗、感染等）、给药途径（口服、肠胃外、外用等）、药物类型（品牌药和仿制药）、治疗领域（联合治疗和单一治疗）、患者类型（老年、成人和儿童）、最终用户（医院、专科诊所、门诊手术中心、家庭护理环境等）、分销渠道（零售药店、直接招标等） |
|
覆盖国家 |
英国、法国、德国、意大利、俄罗斯、西班牙、荷兰、丹麦、瑞士、瑞典、波兰、挪威、芬兰、比利时、土耳其、欧洲其他地区 |
|
涵盖的市场参与者 |
3M（美国）、Cardinal Health（美国）、BD（美国）、Smith + Nephew（英国）、Novartis AG（瑞士）、Amneal Pharmaceuticals LLC.（美国）、Amgen Inc.（美国）、Pfizer Inc.（美国）、Colgate-Palmolive Company（美国）、Merck & Co., Inc.（美国）、Mölnlycke Health Care AB.（瑞典）、Xttrium Laboratories（美国）、Schülke & Mayr GmbH（德国）、ICPA Health Products Ltd（印度）、Purdue Pharma LP（美国）、eugia（Aurobindo Pharma 的子公司）和 AdvaCare Pharma（美国）等 |
市场定义
史蒂文斯-约翰逊综合征 (SJS) 和中毒性表皮坏死松解症 (TEN) 是罕见但危及生命的皮肤病，通常由严重的药物反应引起。这些疾病会导致皮肤表层与下层分离，导致疼痛的水疱和溃疡，可覆盖大部分身体。SJS 影响较小部分的皮肤，而 TEN 影响较大部分的皮肤。
SJS/TEN 治疗的定义是指旨在管理和治疗这些疾病的产品和服务。市场上有药物、疗法和其他治疗方法可以帮助缓解 SJS/TEN 症状并改善患者的生活质量。治疗 SJS/TEN 的药物市场包括许多用于缓解症状和治疗潜在病因的药物。
欧洲 SJS/TEN 治疗市场动态
本节旨在了解市场驱动因素、优势、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
-
SJS/TEN 患病率和发病率不断上升
史蒂文斯-约翰逊综合征 (SJS) 和中毒性表皮坏死松解症 (TEN) 是严重且可能危及生命的皮肤和粘膜疾病。SJS 和 TEN 被认为是疾病谱的两端，其中 SJS 是较轻的形式，而 TEN 是较严重的形式。这些疾病的一个典型特征是由于强烈的免疫反应导致表皮（皮肤外层）与真皮（皮肤下层）分离。
史蒂文斯-约翰逊综合征 (SJS) 和中毒性表皮坏死松解症 (TEN) 是罕见但严重的皮肤病，其特征是表皮与真皮分离。据报道，SJS/TEN 的发病率约为每年每百万人 1 人。然而，近年来，人们对 SJS/TEN 的发病率和患病率越来越关注。
-
SJS/TEN 治疗药物研发进展
史蒂文斯-约翰逊综合征 (SJS) 和中毒性表皮坏死松解症 (TEN) 是严重且可能危及生命的疾病，需要及时积极治疗。虽然目前没有可以治愈 SJS/TEN 的特定药物或治疗方法，但药物开发的进步为受影响的患者带来了更好的治疗策略和治疗结果。但目前正在进行各种临床试验，以开发用于 SJS/TEN 治疗的药物。
克制
-
SJS/TEN 治疗费用高昂
SJS/TEN 治疗费用高昂的主要原因之一是需要进行长期密集治疗。SJS/TEN 患者通常需要在专门的烧伤科住院，在那里接受皮肤科医生、眼科医生和重症监护专家等医疗专业人员团队的 24 小时护理。住院时间可能长达数周，严重情况下甚至长达数月。这可能导致高昂的医院账单和其他相关费用，如交通、住宿和餐饮。
机会
-
开发有效且安全的 SJS/TEN 治疗方法
干细胞移植是一种新方法，旨在用健康组织替换受损的皮肤和粘膜。自体干细胞移植是指从患者皮肤中提取干细胞，在培养皿中培养，然后移植回受损区域，这种移植方法在小型研究中显示出良好的效果。
挑战
- 政府对 SJS/TEN 治疗的审批有严格的规定
政府对 SJS/TEN 治疗审批的严格规定与制药公司及其药物必须经过的复杂而严格的流程有关，以便从美国食品药品监督管理局 (FDA) 或欧洲药品管理局 (EMA) 等监管机构获得 SJS/TEN 治疗的批准。
新药的审批过程通常涉及几阶段的人体临床试验，以评估该药的安全性和有效性。
最新动态
- 2020 年 6 月，欧洲领先的医疗技术公司 BD 宣布已完成对私营公司 Straub Medical AG 的收购。通过此次收购，该公司获得了 Straub Medical AG 的宝贵专业知识和经验，并扩大了其产品组合。这将有助于公司在市场上扩张和成长。
- 2019 年 1 月，Mölnlycke Health Care AB. 收购了 MandJ Airlaid Products A/S，以进一步增强其伤口护理能力。在此次收购中，MandJ 及其员工将成为 Mölnlycke 不可或缺的一部分。此次收购将提高 Mölnlycke 生产先进伤口敷料所需的气流成网材料的供应安全性，并通过加速现有和未来产品的创新和产品开发来帮助伤口护理业务的增长。这将有助于公司在市场上扩张和增长。
欧洲 SJS/TEN 治疗市场范围
欧洲 SJS/TEN 治疗市场根据治疗、诊断、病因、给药途径、药物类型、疗法类型、患者类型、最终用户和分销渠道分为九个值得关注的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
欧洲 SJS/TEN 治疗市场根据治疗、诊断、病因、给药途径、药物类型、治疗类型、患者类型、最终用户和分销渠道分为九个显著部分。
治疗
- 药物
- 支持护理
- 软膏
- 住院
- 隔离
- 其他的
根据治疗，欧洲 SJS/TEN 治疗市场分为药物、支持护理、住院、隔离、药膏和其他。
诊断
- 体格检查
- 病史
- 皮肤活检
- 验血
- 文化
- 其他的
根据诊断，欧洲 SJS/TEN 治疗市场分为体检、皮肤活检、病史、血液检查、培养等。
原因
- 具体治疗
- 感染
- 其他的
根据病因，欧洲 SJS/TEN 治疗市场分为特定治疗、感染和其他治疗。
给药途径
- 口服
- 肠外
- 主题
- 其他的
根据给药途径，欧洲 SJS/TEN 治疗市场分为口服、肠外、外用和其他。
药物类型
- 品牌
- 通用的
根据药物类型，欧洲 SJS/TEN 治疗市场分为品牌药和仿制药。
治疗类型
- 单药治疗
- 联合治疗
根据治疗类型，欧洲 SJS/TEN 治疗市场分为联合治疗和单一治疗。
患者类型
- 儿科
- 成人
- 老年
根据患者类型，欧洲 SJS/TEN 治疗市场分为老年病、成人病和儿童病。
最终用户
- 医院
- 专科诊所
- 门诊手术中心
- 家庭护理环境
- 其他的
根据最终用户，欧洲 SJS/TEN 治疗市场分为医院、专科诊所、门诊手术中心、家庭护理环境和其他。
分销渠道
- 直接招标
- 零售药店
- 其他的
根据分销渠道，欧洲 SJS/TEN 治疗市场分为零售药店、直接招标和其他。
欧洲 SJS/TEN 治疗市场区域分析/见解
欧洲 SJS/TEN 治疗市场根据治疗、诊断、病因、给药途径、药物类型、治疗类型、患者类型、最终用户和分销渠道分为九个显著部分。
本市场报告涵盖的国家包括英国、法国、德国、意大利、俄罗斯、西班牙、荷兰、丹麦、瑞士、瑞典、波兰、挪威、芬兰、比利时、土耳其和欧洲其他地区。
由于 SJS/TEN 治疗药物产量上升、新兴市场需求增加以及医疗保健行业扩张，预计德国将占据主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了欧洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战，以及销售渠道的影响。
竞争格局和欧洲 SJS/TEN 治疗市场份额分析
欧洲 SJS/TEN 治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用主导地位和技术生命线曲线。以上提供的数据点仅与公司对欧洲 SJS/TEN 治疗市场的关注有关。
欧洲 SJS/TEN 治疗市场的一些主要参与者包括 3M（美国）、Cardinal Health（美国）、BD（美国）、Smith + Nephew（英国）、Novartis AG（瑞士）、Amneal Pharmaceuticals LLC.（美国）、Amgen Inc.（美国）、Pfizer Inc.（美国）、高露洁棕榄公司（美国）、默克公司（美国）、Mölnlycke Health Care AB.（瑞典）、Xttrium Laboratories（美国）、Schülke & Mayr GmbH（德国）、ICPA Health Products Ltd（印度）、Purdue Pharma LP（美国）、eugia（Aurobindo Pharma 的子公司）和 AdvaCare Pharma（美国）等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE SJS/TEN TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 KEY TRENDS
4.2 COST OF TREATMENT
4.3 KEY PLAYERS STRATEGIES
4.4 LONG TERM GROWTH APPROACH
5 EPIDEMIOLOGY
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DEMOGRAPHIC TRENDS
6.3 PATIENT FLOW DIAGRAM
6.4 KEY PRICING STRATEGIES
6.5 KEY PATIENT ENROLLMENT STRATEGIES
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN
7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT
7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN
7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN
7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT
7.3 OPPORTUNITIES
7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN
7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT
7.4 CHALLENGES
7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN
7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT
8 EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 MEDICATIONS
8.2.1 ANTIHISTAMINES
8.2.1.1 HYDROXYZINE
8.2.1.2 FEXOFENADINE
8.2.2 CORTICOSTEROID
8.2.2.1 DEXAMETHASONE
8.2.2.2 PREDNISOLONE
8.2.2.3 METHYLPREDNISOLONE
8.2.2.4 HYDROCORTISONE
8.2.2.5 OTHERS
8.2.3 ANTIBIOTICS
8.2.3.1 NAFCILLIN
8.2.3.2 GENTAMICIN
8.2.3.3 OTHERS
8.2.4 ANALGESICS
8.2.4.1 MORPHINE
8.2.4.2 FENTANYL CITRATE
8.2.4.3 OTHERS
8.2.5 ANTICOAGULANTS
8.2.6 ANTISEPTICS
8.2.6.1 CHLORHEXIDINE GLUCONATE
8.2.6.1.1 PERIOGARD
8.2.6.1.2 PERIDEX
8.2.6.1.3 AVAGARD
8.2.6.1.4 HIBICLENS
8.2.6.1.5 OTHERS
8.2.6.2 OCTENISEPT
8.2.6.3 POLYHEXANIDE SOLUTIONS
8.2.6.4 OTHERS
8.2.7 INTRAVENOUS IMMUNOGLOBULIN
8.2.8 CYCLOSPORINE
8.2.8.1 NEORAL
8.2.8.2 SANDIMMUNE
8.2.8.3 OTHERS
8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-Α)‒BLOCKING AGENT (ETANERCEPT)
8.2.10 OTHER TREATMENT
8.2.10.1 CYCLOPHOSPHAMIDE
8.2.10.2 N-ACETYLCYSTEINE
8.2.10.3 MONOCLONAL ANTIBODIES
8.2.10.4 THALIDOMIDE
8.3 SUPPORT CARE
8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES
8.3.2 PAIN MANAGEMENT
8.3.2.1 LIDOCAINE
8.3.2.2 OTHERS
8.3.3 NUTRITION SUPPORT
8.3.4 ORAL CARE
8.3.5 PLASMAPHERESIS
8.3.6 BANDAGES
8.3.6.1 BIOLOGICAL DRESSING
8.3.6.1.1 ALLOGRAFT
8.3.6.1.2 XENOGRAFT
8.3.6.1.3 HOMOGRAFT
8.3.6.1.4 OTHERS
8.3.6.2 BIOSYNTHETIC DRESSING
8.3.6.3 SILVER IMPREGNATED DRESSING
8.4 HOSPITALIZATION
8.5 ISOLATION
8.6 OINTMENTS
8.6.1 BENZOCAINE
8.6.2 AMERICAINE
8.6.3 ANBESOL
8.6.4 CHIGGEREX PLUS
8.6.5 OTHERS
8.7 OTHERS
9 EUROPE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS
9.1 OVERVIEW
9.2 PHYSICAL EXAM
9.3 SKIN BIOPSY
9.4 MEDICAL HISTORY
9.5 BLOOD TEST
9.5.1 COMPLETE BLOOD COUNT
9.5.2 ERYTHROCYTE SEDIMENTATION RATE
9.5.3 COAGULATION STUDIES
9.5.4 UREA AND ELECTROLYTES
9.5.5 LIVER FUNCTION TEST
9.6 CULTURES
9.7 OTHERS
10 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE
10.1 OVERVIEW
10.2 SPECIFIC TREATMENT
10.3 INFECTION
10.4 OTHERS
11 EUROPE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 PARENTERAL
11.3.1 INTRAVENOUS
11.3.2 SUBCUTANEOUS
11.3.3 OTHERS
11.4 TOPICAL
11.4.1 OINTMENTS
11.4.2 SOLUTION
11.4.3 CREAMS
11.4.4 OTHERS
11.5 OTHERS
12 EUROPE SJS/TEN TREATMENT MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 BRANDED
12.2.1 NEORAL
12.2.2 SANDIMMUNE
12.2.3 VISTARIL
12.2.4 DURAMORPH
12.2.5 FENTORA
12.2.6 ENBREL
12.2.7 OTHERS
12.3 GENERIC
13 EUROPE SJS/TEN TREATMENT MARKET, BY THERAPY TYPE
13.1 OVERVIEW
13.2 COMBINATION THERAPY
13.3 MONOTHERAPY
14 EUROPE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE
14.1 OVERVIEW
14.2 GERIATRIC
14.2.1 FEMALE
14.2.2 MALE
14.3 ADULT
14.3.1 FEMALE
14.3.2 MALE
14.4 PEDIATRIC
15 EUROPE SJS/TEN TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 AMBULATORY SURGICAL CENTER
15.5 HOMECARE SETTING
15.6 OTHERS
16 EUROPE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL PHARMACIES
16.2.1 HOSPITAL ASSOCIATED PHARMACIES
16.2.2 DRUG STORE
16.2.3 ONLINE PHARMACIES
16.3 DIRECT TENDERS
16.4 OTHERS
17 EUROPE SJS/TEN TREATMENT MARKET, BY REGION
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 U.K.
17.1.4 ITALY
17.1.5 SPAIN
17.1.6 RUSSIA
17.1.7 TURKEY
17.1.8 BELGIUM
17.1.9 DENMARK
17.1.10 NETHERLANDS
17.1.11 SWITZERLAND
17.1.12 SWEDEN
17.1.13 POLAND
17.1.14 NORWAY
17.1.15 FINLAND
17.1.16 REST OF EUROPE
18 EUROPE SJS/TEN TREATMENT MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 PFIZER INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENT
20.2 NOVARTIS AG
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 MERCK & CO., INC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 AMNEAL PHARMACEUTICAL LLC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENT
20.5 AMGEN INC.
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 ADVACARE PHARMA
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.7 BD
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.8 CARDINAL HEALTH
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 COLGATE-PALMOLIVE COMPANY
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENT
20.1 EUGIA (SUBSIDIARY OF AUROBINDO PHARMA)
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
20.11 ICPA HEALTH PRODUCTS LTD
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 3M
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENT
20.13 MOLNLYCKE HEALTH CARE AB.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.14 PURDUE PHARMA L.P.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 SCHULKE & MAYR GMBH
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 SMITH + NEPHEW
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENT
20.17 XTTRIUM LABORATORIES
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
表格列表
TABLE 1 EUROPE SJS/TEN TREATMENT MARKET, PATENT ANALYSIS
TABLE 2 EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 3 EUROPE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 EUROPE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 5 EUROPE ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 6 EUROPE CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 7 EUROPE ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 8 EUROPE ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 9 EUROPE ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 10 EUROPE CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 11 EUROPE CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 12 EUROPE OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 13 EUROPE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 15 EUROPE PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 16 EUROPE BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 17 EUROPE BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 18 EUROPE HOSPITALIZATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE ISOLATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 EUROPE OINTMENTS IN JS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 EUROPE OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 22 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 EUROPE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 24 EUROPE PHYSICAL EXAM IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 EUROPE SKIN BIOPSY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 EUROPE MEDICAL HISTORY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 EUROPE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 29 EUROPE CULTURES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 32 EUROPE SPECIFIC TREATMENT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 EUROPE INFECTION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 36 EUROPE ORAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 39 EUROPE TOPICAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE TOPICAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 41 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 43 EUROPE BRANDED IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE BRANDED IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 45 EUROPE GENERIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 47 EUROPE COMBINATION THERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 EUROPE MONOTHERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 50 EUROPE GERAITRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 EUROPE GERIATRIC IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 52 EUROPE ADULT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 EUROPE ADULT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 54 EUROPE PEDIATRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 EUROPE SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 56 EUROPE HOSPITALS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 EUROPE SPECIALTY CLINICS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 EUROPE AMBULATORY SURGICAL CENTER IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 EUROPE HOMECARE SETTING IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 EUROPE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 62 EUROPE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 EUROPE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 64 EUROPE DIRECT TENDERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 EUROPE SJS/TEN TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 67 EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 68 EUROPE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 69 EUROPE ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 70 EUROPE CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 71 EUROPE ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 72 EUROPE ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 73 EUROPE ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 74 EUROPE CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 75 EUROPE CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 76 EUROPE OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 77 EUROPE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 78 EUROPE PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 79 EUROPE BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 80 EUROPE BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 81 EUROPE OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 82 EUROPE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 83 EUROPE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 84 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 85 EUROPE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 86 EUROPE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 87 EUROPE TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 88 EUROPE SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 EUROPE BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 90 EUROPE SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 91 EUROPE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 92 EUROPE GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 93 EUROPE ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 94 EUROPE SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 95 EUROPE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 96 EUROPE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 97 GERMANY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 98 GERMANY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 99 GERMANY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 100 GERMANY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 101 GERMANY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 102 GERMANY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 103 GERMANY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 104 GERMANY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 105 GERMANY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 106 GERMANY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 107 GERMANY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 108 GERMANY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 109 GERMANY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 110 GERMANY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 111 GERMANY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 112 GERMANY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 113 GERMANY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 114 GERMANY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 115 GERMANY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 116 GERMANY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 117 GERMANY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 118 GERMANY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 119 GERMANY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 120 GERMANY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 121 GERMANY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 122 GERMANY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 123 GERMANY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 124 GERMANY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 125 GERMANY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 126 GERMANY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 FRANCE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 128 FRANCE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 129 FRANCE ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 130 FRANCE CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 131 FRANCE ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 132 FRANCE ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 133 FRANCE ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 134 FRANCE CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 135 FRANCE CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 136 FRANCE OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 137 FRANCE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 138 FRANCE PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 139 FRANCE BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 140 FRANCE BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 141 FRANCE OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 142 FRANCE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 143 FRANCE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 144 FRANCE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 145 FRANCE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 146 FRANCE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 147 FRANCE TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 148 FRANCE SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 149 FRANCE BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 150 FRANCE SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 151 FRANCE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 152 FRANCE GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 153 FRANCE ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 154 FRANCE SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 155 FRANCE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 156 FRANCE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 157 U.K. SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 158 U.K. MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 159 U.K. ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 160 U.K. CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 161 U.K. ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 162 U.K. ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 163 U.K. ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 164 U.K. CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 165 U.K. CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 166 U.K. OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 167 U.K. SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 168 U.K. PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 169 U.K. BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 170 U.K. BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 171 U.K. OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 172 U.K. SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 173 U.K. BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 174 U.K. SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 175 U.K. SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 176 U.K. PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 177 U.K. TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 178 U.K. SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 U.K. BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 180 U.K. SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 181 U.K. SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 182 U.K. GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 183 U.K. ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 184 U.K. SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 185 U.K. SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 186 U.K. RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 187 ITALY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 188 ITALY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 189 ITALY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 190 ITALY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 191 ITALY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 192 ITALY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 193 ITALY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 194 ITALY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 195 ITALY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 196 ITALY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 197 ITALY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 198 ITALY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 199 ITALY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 200 ITALY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 201 ITALY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 202 ITALY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 203 ITALY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 204 ITALY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 205 ITALY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 206 ITALY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 207 ITALY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 208 ITALY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 209 ITALY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 210 ITALY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 211 ITALY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 212 ITALY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 213 ITALY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 214 ITALY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 215 ITALY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 216 ITALY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 217 SPAIN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 218 SPAIN MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 219 SPAIN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 220 SPAIN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 221 SPAIN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 222 SPAIN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 223 SPAIN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 224 SPAIN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 225 SPAIN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 226 SPAIN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 227 SPAIN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 228 SPAIN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 229 SPAIN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 230 SPAIN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 231 SPAIN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 232 SPAIN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 233 SPAIN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 234 SPAIN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 235 SPAIN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 236 SPAIN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 237 SPAIN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 238 SPAIN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 239 SPAIN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 240 SPAIN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 241 SPAIN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 242 SPAIN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 243 SPAIN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 244 SPAIN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 245 SPAIN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 246 RUSSIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 247 RUSSIA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 248 RUSSIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 249 RUSSIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 250 RUSSIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 251 RUSSIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 252 RUSSIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 253 RUSSIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 254 RUSSIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 255 RUSSIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 256 RUSSIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 257 RUSSIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 258 RUSSIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 259 RUSSIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 260 RUSSIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 261 RUSSIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 262 RUSSIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 263 RUSSIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 264 RUSSIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 265 RUSSIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 266 RUSSIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 267 RUSSIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 268 RUSSIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 269 RUSSIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 270 RUSSIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 271 RUSSIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 272 RUSSIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 273 RUSSIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 274 RUSSIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 275 RUSSIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 276 TURKEY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 277 TURKEY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 278 TURKEY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 279 TURKEY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 280 TURKEY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 281 TURKEY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 282 TURKEY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 283 TURKEY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 284 TURKEY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 285 TURKEY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 286 TURKEY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 287 TURKEY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 288 TURKEY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 289 TURKEY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 290 TURKEY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 291 TURKEY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 292 TURKEY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 293 TURKEY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 294 TURKEY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 295 TURKEY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 296 TURKEY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 297 TURKEY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 298 TURKEY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 299 TURKEY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 300 TURKEY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 301 TURKEY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 302 TURKEY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 303 TURKEY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 304 TURKEY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 305 TURKEY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 306 BELGIUM SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 307 BELGIUM MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 308 BELGIUM ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 309 BELGIUM CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 310 BELGIUM ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 311 BELGIUM ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 312 BELGIUM ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 313 BELGIUM CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 314 BELGIUM CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 315 BELGIUM OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 316 BELGIUM SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 317 BELGIUM PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 318 BELGIUM BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 319 BELGIUM BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 320 BELGIUM OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 321 BELGIUM SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 322 BELGIUM BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 323 BELGIUM SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 324 BELGIUM SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 325 BELGIUM PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 326 BELGIUM TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 327 BELGIUM SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 328 BELGIUM BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 329 BELGIUM SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 330 BELGIUM SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 331 BELGIUM GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 332 BELGIUM ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 333 BELGIUM SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 334 BELGIUM SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 335 BELGIUM RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 336 DENMARK SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 337 DENMARK MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 338 DENMARK ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 339 DENMARK CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 340 DENMARK ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 341 DENMARK ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 342 DENMARK ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 343 DENMARK CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 344 DENMARK CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 345 DENMARK OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 346 DENMARK SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 347 DENMARK PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 348 DENMARK BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 349 DENMARK BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 350 DENMARK OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 351 DENMARK SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 352 DENMARK BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 353 DENMARK SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 354 DENMARK SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 355 DENMARK PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 356 DENMARK TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 357 DENMARK SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 358 DENMARK BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 359 DENMARK SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 360 DENMARK SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 361 DENMARK GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 362 DENMARK ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 363 DENMARK SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 364 DENMARK SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 365 DENMARK RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 366 NETHERLANDS SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 367 NETHERLANDS MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 368 NETHERLANDS ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 369 NETHERLANDS CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 370 NETHERLANDS ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 371 NETHERLANDS ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 372 NETHERLANDS ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 373 NETHERLANDS CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 374 NETHERLANDS CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 375 NETHERLANDS OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 376 NETHERLANDS SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 377 NETHERLANDS PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 378 NETHERLANDS BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 379 NETHERLANDS BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 380 NETHERLANDS OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 381 NETHERLANDS SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 382 NETHERLANDS BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 383 NETHERLANDS SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 384 NETHERLANDS SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 385 NETHERLANDS PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 386 NETHERLANDS TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 387 NETHERLANDS SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 388 NETHERLANDS BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 389 NETHERLANDS SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 390 NETHERLANDS SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 391 NETHERLANDS GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 392 NETHERLANDS ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 393 NETHERLANDS SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 394 NETHERLANDS SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 395 NETHERLANDS RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 396 SWITZERLAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 397 SWITZERLAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 398 SWITZERLAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 399 SWITZERLAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 400 SWITZERLAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 401 SWITZERLAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 402 SWITZERLAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 403 SWITZERLAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 404 SWITZERLAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 405 SWITZERLAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 406 SWITZERLAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 407 SWITZERLAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 408 SWITZERLAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 409 SWITZERLAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 410 SWITZERLAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 411 SWITZERLAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 412 SWITZERLAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 413 SWITZERLAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 414 SWITZERLAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 415 SWITZERLAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 416 SWITZERLAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 417 SWITZERLAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 418 SWITZERLAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 419 SWITZERLAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 420 SWITZERLAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 421 SWITZERLAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 422 SWITZERLAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 423 SWITZERLAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 424 SWITZERLAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 425 SWITZERLAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 426 SWEDEN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 427 SWEDEN MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 428 SWEDEN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 429 SWEDEN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 430 SWEDEN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 431 SWEDEN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 432 SWEDEN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 433 SWEDEN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 434 SWEDEN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 435 SWEDEN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 436 SWEDEN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 437 SWEDEN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 438 SWEDEN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 439 SWEDEN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 440 SWEDEN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 441 SWEDEN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 442 SWEDEN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 443 SWEDEN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 444 SWEDEN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 445 SWEDEN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 446 SWEDEN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 447 SWEDEN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 448 SWEDEN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 449 SWEDEN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 450 SWEDEN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 451 SWEDEN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 452 SWEDEN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 453 SWEDEN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 454 SWEDEN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 455 SWEDEN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 456 POLAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 457 POLAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 458 POLAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 459 POLAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 460 POLAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 461 POLAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 462 POLAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 463 POLAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 464 POLAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 465 POLAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 466 POLAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 467 POLAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 468 POLAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 469 POLAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 470 POLAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 471 POLAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 472 POLAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 473 POLAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 474 POLAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 475 POLAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 476 POLAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 477 POLAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 478 POLAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 479 POLAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 480 POLAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 481 POLAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 482 POLAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 483 POLAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 484 POLAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 485 POLAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 486 NORWAY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 487 NORWAY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 488 NORWAY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 489 NORWAY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 490 NORWAY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 491 NORWAY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 492 NORWAY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 493 NORWAY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 494 NORWAY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 495 NORWAY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 496 NORWAY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 497 NORWAY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 498 NORWAY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 499 NORWAY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 500 NORWAY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 501 NORWAY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 502 NORWAY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 503 NORWAY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 504 NORWAY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 505 NORWAY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 506 NORWAY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 507 NORWAY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 508 NORWAY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 509 NORWAY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 510 NORWAY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 511 NORWAY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 512 NORWAY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 513 NORWAY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 514 NORWAY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 515 NORWAY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 516 FINLAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 517 FINLAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 518 FINLAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 519 FINLAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 520 FINLAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 521 FINLAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 522 FINLAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 523 FINLAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 524 FINLAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 525 FINLAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 526 FINLAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 527 FINLAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 528 FINLAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 529 FINLAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 530 FINLAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 531 FINLAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 532 FINLAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 533 FINLAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 534 FINLAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 535 FINLAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 536 FINLAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 537 FINLAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 538 FINLAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 539 FINLAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 540 FINLAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 541 FINLAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 542 FINLAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 543 FINLAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 544 FINLAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 545 FINLAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 546 REST OF EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 EUROPE SJS/TEN TREATMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE SJS/TEN TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE SJS/TEN TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE SJS/TEN TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE SJS/TEN TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE SJS/TEN TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE SJS/TEN TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE SJS/TEN TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE SJS/TEN TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE SJS/TEN TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN ARE EXPECTED TO DRIVE THE EUROPE SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD FROM 2023 TO 2030
FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD OF 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE SJS/TEN TREATMENT MARKET
FIGURE 14 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT, 2022
FIGURE 15 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT, CAGR (2023-2030)
FIGURE 17 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 EUROPE SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2022
FIGURE 19 EUROPE SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2023-2030 (USD MILLION)
FIGURE 20 EUROPE SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, CAGR (2023-2030)
FIGURE 21 EUROPE SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 22 EUROPE SJS/TEN TREATMENT MARKET: BY CAUSE, 2022
FIGURE 23 EUROPE SJS/TEN TREATMENT MARKET: BY CAUSE, 2023-2030 (USD MILLION)
FIGURE 24 EUROPE SJS/TEN TREATMENT MARKET: BY CAUSE, CAGR (2023-2030)
FIGURE 25 EUROPE SJS/TEN TREATMENT MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 26 EUROPE SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 27 EUROPE SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 29 EUROPE SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 EUROPE SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2022
FIGURE 31 EUROPE SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 32 EUROPE SJS/TEN TREATMENT MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 33 EUROPE SJS/TEN TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 34 EUROPE SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2022
FIGURE 35 EUROPE SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2023-2030 (USD MILLION)
FIGURE 36 EUROPE SJS/TEN TREATMENT MARKET: BY THERAPY AREA, CAGR (2023-2030)
FIGURE 37 EUROPE SJS/TEN TREATMENT MARKET: BY THERAPY AREA, LIFELINE CURVE
FIGURE 38 EUROPE SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2022
FIGURE 39 EUROPE SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2023-2030 (USD MILLION)
FIGURE 40 EUROPE SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, CAGR (2023-2030)
FIGURE 41 EUROPE SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 42 EUROPE SJS/TEN TREATMENT MARKET: BY END USER, 2022
FIGURE 43 EUROPE SJS/TEN TREATMENT MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 44 EUROPE SJS/TEN TREATMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 45 EUROPE SJS/TEN TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 46 EUROPE SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 47 EUROPE SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 48 EUROPE SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 49 EUROPE SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 50 EUROPE SJS/TEN TREATMENT MARKET: SNAPSHOT (2022)
FIGURE 51 EUROPE SJS/TEN TREATMENT MARKET: BY COUNTRY (2022)
FIGURE 52 EUROPE SJS/TEN TREATMENT MARKET: BY COUNTRY (2023 & 2030)
FIGURE 53 EUROPE SJS/TEN TREATMENT MARKET: BY COUNTRY (2022 & 2030)
FIGURE 54 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT (2023-2030)
FIGURE 55 EUROPE SJS/TEN TREATMENT MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
